X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (13) 13
humans (12) 12
female (11) 11
male (11) 11
middle aged (10) 10
aged (8) 8
chemotherapy (8) 8
oncology (8) 8
adult (7) 7
hematology (7) 7
clinical trials (6) 6
leukemia, myeloid, acute - mortality (6) 6
cancer (5) 5
leukemia, myeloid, acute - drug therapy (5) 5
survival (5) 5
therapy (5) 5
transplantation (5) 5
bone marrow (4) 4
drug dosages (4) 4
hematology, oncology and palliative medicine (4) 4
multiple myeloma (4) 4
recurrence (4) 4
stem cells (4) 4
stem-cell transplantation (4) 4
survival analysis (4) 4
transplants & implants (4) 4
abridged index medicus (3) 3
acute myelogenous leukemia (3) 3
aged, 80 and over (3) 3
analysis (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
hematopoietic stem cell transplantation - methods (3) 3
leukemia (3) 3
medicine, general & internal (3) 3
mortality (3) 3
multiple myeloma - therapy (3) 3
patients (3) 3
prognosis (3) 3
risk factors (3) 3
transplantation, homologous (3) 3
treatment outcome (3) 3
acute myeloid leukemia (2) 2
acute myeloid-leukemia (2) 2
adolescent (2) 2
age factors (2) 2
aml (2) 2
antimetabolites, antineoplastic - therapeutic use (2) 2
bone-marrow-transplantation (2) 2
bortezomib (2) 2
care and treatment (2) 2
colony-stimulating factor (2) 2
combination (2) 2
consolidation (2) 2
cytarabine (2) 2
cytarabine - administration & dosage (2) 2
cytarabine - therapeutic use (2) 2
daunorubicin - administration & dosage (2) 2
dexamethasone (2) 2
diagnosis (2) 2
disease-free survival (2) 2
diseases (2) 2
elderly-patients (2) 2
fms-like tyrosine kinase 3 - genetics (2) 2
germany (2) 2
hematopoietic stem cell transplantation (2) 2
hematopoietic stem cells (2) 2
hemic and lymphatic diseases (2) 2
high-dose cytarabine (2) 2
high-dose therapy (2) 2
immunology (2) 2
immunotherapy (2) 2
impact (2) 2
induction (2) 2
induction chemotherapy (2) 2
internal medicine (2) 2
kinases (2) 2
leukemia, myeloid, acute - diagnosis (2) 2
leukemia, myeloid, acute - therapy (2) 2
maximum tolerated dose (2) 2
medical prognosis (2) 2
medical research (2) 2
motivation (2) 2
multiple myeloma - diagnosis (2) 2
mutation (2) 2
mutations (2) 2
myelodysplastic syndrome (2) 2
neutropenia (2) 2
oncology, experimental (2) 2
plasma (2) 2
pneumonia (2) 2
proportional hazards models (2) 2
randomization (2) 2
relapse (2) 2
remission (2) 2
remission induction (2) 2
research (2) 2
retrospective studies (2) 2
risk assessment (2) 2
safety (2) 2
standards (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 8, pp. 1061 - 1075
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9757, pp. 2000 - 2008
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2016, Volume 22, Issue 11, pp. 1988 - 1996
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1691 - 1699
Summary Background Preclinical data and results from non-randomised trials suggest that the multikinase inhibitor sorafenib might be an effective drug for the... 
Hematology, Oncology and Palliative Medicine | AML | ONCOLOGY | ACUTE MYELOGENOUS LEUKEMIA | BONE-MARROW | CLASSIFICATION | FLT3 MUTATIONS | CYTARABINE | STEM-CELL TRANSPLANTATION | COMBINATION | ELDERLY-PATIENTS | CHEMOTHERAPY | Niacinamide - analogs & derivatives | Recurrence | Age Factors | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Transplantation, Homologous | Neoadjuvant Therapy - mortality | Time Factors | Phenylurea Compounds - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Chemotherapy, Adjuvant | Daunorubicin - therapeutic use | Double-Blind Method | Risk Factors | Kaplan-Meier Estimate | Niacinamide - adverse effects | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Disease Progression | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Leukemia, Myeloid, Acute - diagnosis | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - adverse effects | Protein Kinase Inhibitors - therapeutic use | Germany | Antimitotic agents | Clinical trials | Chemotherapy | Antineoplastic agents | Standards | Cancer
Journal Article
by Dimopoulos, Meletios A and Dimopoulos, Athanasios and Gay, Francesca and Schjesvold, Fredrik and Beksac, Meral and Hajek, Roman and Weisel, Katja Christina and Weisel, Katja and Goldschmidt, Hartmut and Maisnar, Vladimir and Moreau, Philippe and Min, Chang Ki and Pluta, Andrzej and Pluta, Agnieszka and Chng, Wee Joo and Chng, Wee-Joo and Kaiser, Martin and Zweegman, Sonja and Mateos, Maria-Victoria and Mateos, Maria Victoria and Spencer, Andrew and Iida, Shinsuke and Morgan, Gareth and Suryanarayan, Kaveri and Teng, Zhaoyang and Skacel, Tomas and Palumbo, Antonio and Dash, Ajeeta B and Gupta, Neeraj and Labotka, Richard and Rajkumar, S Vincent and Bar, Daniel and Basso, Alfredo and Fantl, Dorotea and He, Simon and Horvath, Neomi and Lee, Cindy and Lee, Jae Hoon and Rowlings, Phillip and Taylor, Kerry and Cochrane, Tara and Kwok, Fiona and Ramanathan, Sundreswran and Agis, Hermine and Zojer, Niklas and Kentos, Alain and Offner, Fritz and Van Droogenbroeck, Jan and Wu, Ka Lung and Maiolino, Angelo and Martinez, Gracia and Zanella, Karla and Capra, Marcelo and Araújo, Sérgio and Gregora, Evzen and Pour, Ludek and Scudla, Vlastimil and Spicka, Ivan and Abildgaard, Niels and Andersen, Niels and Jensen, Bo Amdi and Helleberg, Carsten and Plesner, Torben and Salomo, Morten and Svirskaite, Asta and Delarue, Richard and Blau, Igor and Schieferdecker, Aneta and Teleanu, Veronica and Munder, Markus and Röllig, Christoph and Salwender, Han-Juergen and Fuhrmann, Stephan and Duerig, Jan and Zeis, Matthias and Klein, Stefan and Reimer, Peter and Schmidt, Christian and Scheid, Christof and Mayer, Karin and Hoffmann, Martin and Sosada, Markus and Delimpasi, Sosana and Kyrtsonis, Mary-Christine and Anagnostopoulos, Achilleas and Nagy, Zsolt and Illés, Árpád and Egyed, Miklós and Borbényi, Zita and Mikala, Gabor and Dally, Najib and Horowitz, Netanel and Gutwein, Odit and Nemets, Anatoly and Vaxman, Iuliana and Shvetz, Olga and Trestman, Svetlana and Ruchlemer, Rosa and Nagler, Arnon and Tadmor, Tamar and ... and TOURMALINE-MM3 Study Grp and TOURMALINE-MM3 study group
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10168, pp. 253 - 264
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2012, Volume 7, Issue 12, pp. e52695 - e52695
Introduction: Older patients with acute myeloid leukemia (AML) experience short survival despite intensive chemotherapy. Azacitidine has promising activity in... 
CONVENTIONAL CARE REGIMENS | PROGNOSTIC IMPACT | IDH2 MUTATIONS | 5-AZACYTIDINE | RECOMMENDATIONS | MULTIDISCIPLINARY SCIENCES | TET2 | RISK MYELODYSPLASTIC SYNDROMES | DNMT3A MUTATIONS | INDUCTION | CHRONIC MYELOMONOCYTIC LEUKEMIA | Humans | Middle Aged | Induction Chemotherapy | Male | Treatment Outcome | Consolidation Chemotherapy | Cytarabine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - toxicity | Feasibility Studies | Leukemia, Myeloid, Acute - mortality | Maximum Tolerated Dose | Pilot Projects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Daunorubicin - administration & dosage | Azacitidine - administration & dosage | Anthracyclines | Chemotherapy | Analysis | Oncology, Experimental | Clinical trials | Aged patients | Research | Standards | Cancer | Toxicity | Leukemia | Brain cancer | Oncology | Cardiovascular disease | Kinases | Randomization | Cytarabine | Daunorubicin | Consolidation | Safety engineering | DNA methylation | Bone marrow | Remission | Heart diseases | Drug dosages | Deoxyribonucleic acid--DNA | Medical research | Hematology | Myeloid leukemia | Feasibility studies | Patients | Survival | Constraining | White blood cells | Medicine | Medical prognosis | Mutation | Acute myeloid leukemia | Index Medicus | Deoxyribonucleic acid | DNA
Journal Article
Journal Article